Masimo appointed Katie Szyman as its next chief executive officer after a proxy fight forced out the company’s founder.

After its longtime chief was ousted last year following a proxy battle, Masimo has now appointed a new CEO. | The medtech has ...

(This Jan. 21 story has been corrected to fix the share price gain to 57% from 45% in paragraph 6) (Reuters) - Masimo named Becton Dickinson executive Katie Szyman as its top boss, the medical device ...

Szyman led Edwards Lifesciences’ critical care unit for more than a decade before BD acquired the group last year. Her ...

Looking ahead to 2025, Masimo projects healthcare revenues to land between $1.5 billion and $1.53 billion. That would deliver ...

MASI's revenue growth in the fourth quarter is likely to have been boosted by the continued robust adoption of its products.

Masimo (Nasdaq: MASI) + Masimo Corporation $172.4 1.44% Open 173.198 Day High 175.067 52 Week High 147.89 52 Week Low 75.22 announced today that it appointed Katie Szyman as its new CEO, effective Feb ...

Today the Board of Directors (the “Board”) of Masimo (NASDAQ: MASI), a leading global medical innovator, announced that Katie Szyman has been appointe ...

Piper Sandler analyst Jason Bednar maintained a Buy rating on Masimo (MASI – Research Report) today and set a price target of $210.00. The ...

Masimo named Becton Dickinson executive Katie Szyman as its top boss, the medical device maker said on Tuesday, months after longtime CEO and founder Joe Kiani was ousted in a bitter proxy battle with ...

Masimo Corp. today announced Katie Szyman as its new chief executive, effective Feb. 12. Szyman is currently worldwide ...

Masimo (MASI) announced that Katie Szyman has been appointed the next Chief Executive Officer of the Company. Interim CEO Michelle Brennan has ...